Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

1.

Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.

Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M, Volante M.

J Clin Endocrinol Metab. 2011 Jul;96(7):2146-53. doi: 10.1210/jc.2010-2655. Epub 2011 May 4.

PMID:
21543427
[PubMed - indexed for MEDLINE]
2.

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM, Lacroix L.

J Clin Endocrinol Metab. 2012 Oct;97(10):E2031-5. doi: 10.1210/jc.2012-2092. Epub 2012 Aug 3.

PMID:
22865907
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

Moura MM, Cavaco BM, Pinto AE, Leite V.

J Clin Endocrinol Metab. 2011 May;96(5):E863-8. doi: 10.1210/jc.2010-1921. Epub 2011 Feb 16.

PMID:
21325462
[PubMed - indexed for MEDLINE]
4.

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9.

PMID:
15316058
[PubMed - indexed for MEDLINE]
Free Article
5.

The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.

Kushchayeva Y, Jensen K, Recupero A, Costello J, Patel A, Klubo-Gwiezdzinska J, Boyle L, Burman K, Vasko V.

J Clin Endocrinol Metab. 2014 May;99(5):E734-45. doi: 10.1210/jc.2013-3369. Epub 2014 Jan 31.

PMID:
24483157
[PubMed - indexed for MEDLINE]
6.

mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.

Faustino A, Couto JP, Pópulo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simões M, Soares P.

J Clin Endocrinol Metab. 2012 Jul;97(7):E1139-49. doi: 10.1210/jc.2011-2748. Epub 2012 May 1.

PMID:
22549934
[PubMed - indexed for MEDLINE]
7.

Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.

Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M.

Anticancer Res. 2011 Dec;31(12):4179-83.

PMID:
22199277
[PubMed - indexed for MEDLINE]
8.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.

Clin Cancer Res. 2006 Mar 15;12(6):1785-93.

PMID:
16551863
[PubMed - indexed for MEDLINE]
Free Article
9.

Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.

Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M.

J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22.

PMID:
22442268
[PubMed - indexed for MEDLINE]
10.

PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

Perrone F, Da Riva L, Orsenigo M, Losa M, Jocollè G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S.

Neuro Oncol. 2009 Dec;11(6):725-36. doi: 10.1215/15228517-2009-003. Epub .

PMID:
19246520
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.

Arthan D, Hong SK, Park JI.

Cancer Lett. 2010 Nov 1;297(1):31-41. doi: 10.1016/j.canlet.2010.04.021. Epub 2010 May 31.

PMID:
20570039
[PubMed - indexed for MEDLINE]
12.

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F.

J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14.

PMID:
15240784
[PubMed - indexed for MEDLINE]
Free Article
13.

Functional significance of the novel H-RAS gene mutation M72I in a patient with medullary thyroid cancer.

Barollo S, Pezzani R, Cristiani A, Bertazza L, Rubin B, Bulfone A, Pelizzo MR, Torresan F, Mantero F, Pennelli G, Moro S, Mian C.

Exp Clin Endocrinol Diabetes. 2013 Oct;121(9):546-50. doi: 10.1055/s-0033-1351299. Epub 2013 Aug 9.

PMID:
23934677
[PubMed - indexed for MEDLINE]
14.

In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.

Prazeres H, Couto JP, Rodrigues F, Vinagre J, Torres J, Trovisco V, Martins TC, Sobrinho-Simões M, Soares P.

Endocr Relat Cancer. 2011 Jul 1;18(4):401-12. doi: 10.1530/ERC-10-0258. Print 2011 Aug.

PMID:
21551259
[PubMed - indexed for MEDLINE]
Free Article
15.

Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.

Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM, Borrello MG, Basolo F, Ugolini C, Materazzi G, Pinchera A, Elisei R.

Thyroid. 2013 Jan;23(1):50-7. doi: 10.1089/thy.2012.0207. Epub 2012 Dec 16.

PMID:
23240926
[PubMed - indexed for MEDLINE]
16.

Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.

Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, Böhm BO, Schmid RM.

Cancer Res. 2001 Jun 1;61(11):4526-35.

PMID:
11389085
[PubMed - indexed for MEDLINE]
Free Article
17.

Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.

Gallel P, Pallares J, Dolcet X, Llobet D, Eritja N, Santacana M, Yeramian A, Palomar-Asenjo V, Lagarda H, Mauricio D, Encinas M, Matias-Guiu X.

Hum Pathol. 2008 Jul;39(7):994-1001. doi: 10.1016/j.humpath.2007.11.015. Epub 2008 May 27.

PMID:
18508109
[PubMed - indexed for MEDLINE]
18.

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.

Simbolo M, Mian C, Barollo S, Fassan M, Mafficini A, Neves D, Scardoni M, Pennelli G, Rugge M, Pelizzo MR, Cavedon E, Fugazzola L, Scarpa A.

Virchows Arch. 2014 Jul;465(1):73-8. doi: 10.1007/s00428-014-1589-3. Epub 2014 May 15.

PMID:
24828033
[PubMed - indexed for MEDLINE]
19.

Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.

Gorla L, Mondellini P, Cuccuru G, Miccichè F, Cassinelli G, Cremona M, Pierotti MA, Lanzi C, Bongarzone I.

Mol Carcinog. 2009 Mar;48(3):220-31. doi: 10.1002/mc.20474.

PMID:
18756447
[PubMed - indexed for MEDLINE]
20.

Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.

Ruiz A, Antiñolo G, Fernández RM, Eng C, Marcos I, Borrego S.

Clin Endocrinol (Oxf). 2001 Sep;55(3):399-402.

PMID:
11589684
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk